Caris Life Sciences (CAI): Initiation of Coverage (FY2023-FY2025, Q4 2025-Q2 2026)
Key Points
- Transformational Growth: Revenue nearly doubled in FY2025 to $812.0M (+97% YoY), with continued strong growth into 2026 (Q2 2026 revenue +45% YoY).
- Path to Profitability: Net loss narrowed sharply in FY2025 (-$68.1M vs. -$281.9M FY2024); Adjusted EBITDA turned positive ($137.7M FY2025). Positive free cash flow since Q2 2025.
- Product & Platform Expansion: Major launches include MI Cancer Seek (FDA-approved, Jan 2025), Caris Assure (blood-based profiling), and Caris Detect (MCED, launched Q2 2026).
- Strong Balance Sheet: $800M+ in cash post-IPO (June 2025), supporting reinvestment in pipeline and commercial expansion.
- Margin Expansion: Gross margin improved from 37.5% (Q2 2024) to 75% (Q4 2025), sustaining at 65-68% in 2026.
- Operational Leverage: Clinical case volumes up 22% YoY in FY2025; blended ASP per profile up 52% YoY in Q2 2025.
- Competitive Position: Large proprietary clinico-genomic dataset (>1.13M profiles), differentiated WES/WTS/WGS platform, and strategic biopharma partnerships.
Summary Table: Key Material Information
Fiscal Year Financials (FY2023-FY2025)
| Fiscal Year | Revenue ($M) | Revenue Growth (%) | Net Loss ($M) | Adj. EBITDA ($M) | Free Cash Flow ($M) | Cash & Equiv. ($M) | Total Debt ($M) | Clinical Cases (MI Profile) | Clinical Cases (Caris Assure) |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 812.0 | +97.0 | -68.1 | 137.7 | 66.9 | 800.0 | 400.0 | 170,300 | 29,000 |
| 2024 | 412.3 | +34.7 | -281.9 | -189.6 | -253.6 | 68.0 | 373.1 | 146,600 | 16,250 |
| 2023 | 306.1 | - | -341.4 | - | - | 60.0 | - | - | - |
Quarterly Financials (Q4 2025-Q2 2026)
| Quarter | Revenue ($M) | Molecular Profiling Revenue ($M) | Clinical Case Volume | Gross Margin (%) | Adj. EBITDA ($M) | Free Cash Flow ($M) | Cash & Investments ($M) |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 263.7 | 252.3 | 59,200 | 68 | 55.7 | 6.4 | 793 |
| Q1 2026 | 216.0 | 211.0 | 52,800 | 65 | 26.0 | 22.5 | 825 |
| Q4 2025 | 293.0 | 282.0 | - | 75 | 106.0 | 39.7 | 800+ |
Segment Revenue Mix (Selected Periods)
| Period | Molecular Profiling Revenue ($M) | Pharma R&D Revenue ($M) | Total Revenue ($M) |
|---|---|---|---|
| Q2 2025 | 162.9 | 18.5 | 181.4 |
| FY 2025 | 766.7 | 45.3 | 812.0 |
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Sustained high revenue growth (+97% FY2025, +45-125% recent quarters) | Still unprofitable on a GAAP basis (FY2025 net loss -$68.1M) |
| Consistent positive adjusted EBITDA and free cash flow since Q2 2025 | High R&D and SG&A expenses; cost structure remains elevated |
| Gross margin expansion (from 37.5% Q2 2024 to 75% Q4 2025, sustaining at 65-68%) | Heavy reliance on tissue-based profiling (84.4% of FY2025 revenue) |
| Strong cash position post-IPO ($800M+) | Pharma R&D revenue declined -28.2% YoY in FY2025; remains lumpy |
| Large proprietary data set (>1.13M profiles) and differentiated WES/WTS/WGS platform | Competitive market with well-capitalized players (Foundation Medicine, Guardant, Tempus, etc.) |
| Rapid commercial expansion and successful new product launches (MI Cancer Seek, Caris Detect) | Ongoing regulatory, reimbursement, and legal risks (e.g., DOJ investigation, internal controls) |
| Positive payer traction (MI Cancer Seek >239M covered lives, Caris Assure >131M) | Execution risk in scaling new channels and integrating new hires |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Commercial ramp and adoption of Caris Detect (MCED) | Delays or setbacks in MRD pipeline validation/launch |
| Expansion of payer coverage for Caris Assure and new tests | Reimbursement headwinds or pricing pressure (PAMA, CRUSH) |
| Further gross margin improvement via scale and new suppliers | Slower-than-expected sales force productivity ramp |
| Additional channel partnerships (e.g., Everlywell) | Capacity constraints or operational hiccups in scaling MCED |
| New product launches (ChromoSeq, MI Clarity V2, MRD) | Increased competition in MCED/liquid biopsy |
| Potential M&A or strategic partnerships | Lumpy/lower pharma R&D revenue contribution |
| Share repurchase program ($100M authorized) | Regulatory delays (e.g., NY State approval for Assure) |
| Resolution of DOJ investigation and remediation of internal control material weakness | Legal or compliance issues |
Top Questions to Ask Before Investing
MCED Adoption and Economics:
- What is the early uptake of Caris Detect? How sustainable is demand, and what are the economics (COGS, ASP, margin trajectory) as volumes ramp?
- How does Caris plan to differentiate and compete against established MCED players (e.g., Guardant, GRAIL)?
Pipeline Execution:
- What are the timelines and regulatory/reimbursement pathways for MRD (tumor-naive and tumor-informed) and other pipeline products?
- What is the expected contribution from new launches (ChromoSeq, MI Clarity V2) to revenue and margin?
Commercial Expansion ROI:
- How quickly are new sales hires and territory expansions translating into incremental volume and revenue?
- What is the target size for the commercial organization, and how is productivity measured?
Reimbursement and Pricing Stability:
- What is the outlook for ASPs and payer coverage, especially in light of PAMA reporting and CRUSH initiatives?
- Are there any risks of downward pricing adjustments for key assays?
Capacity and Operational Scaling:
- Is current lab and sequencing capacity sufficient to meet projected demand for MCED and other products?
- What are the plans for further CapEx, and how will new sequencing suppliers impact cost structure?
Pharma R&D and Data Monetization:
- What is the outlook for pharma R&D revenue, and how material is the AI/data licensing opportunity?
- How does Caris plan to convert its large data set into recurring revenue streams?
Financial Discipline and Capital Allocation:
- How will management balance reinvestment in growth with maintaining profitability and cash flow?
- What is the strategy for share repurchases and potential M&A?
